Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ibandronate sodium monohydrate (BM-210955) 是一种高活性的含氮二磷酸盐,可用于骨质疏松。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 137 | 现货 | ||
25 mg | ¥ 198 | 现货 | ||
50 mg | ¥ 289 | 现货 |
产品描述 | Ibandronate sodium monohydrate (BM-210955) is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis. |
体外活性 | Ibandronate (1.25–2 μM) significantly reduces endothelial cell growth, while ibandronate (2 μM) also significantly reduces capillary-like tube formation and increases apoptosis of endothelial cells. Ibandronate (< 100 μM) dose-dependently increases VEGF expression in endothelial cells. [1] Ibandronate (< 100 μM) inhibits growth of both prostate cancer cell lines (LNCaP and PC-3) in a dose dependent manner. [2] |
体内活性 | Ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months) significantly reduces the risk of new morphometric vertebral fractures by 62% and 50% (p = 0.0006), respectively, in osteoporotic women after 3 years' treatment. Ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months) significantly and progressively increases BMD of lumbar spine by 6.5% and 5.7%, respectively, in osteoporotic women after 3 years' treatment. [3] Ibandronate (< 125 mg/kg s.c.) results in a dose dependent increase in bone mineral density (BMD), trabecular bone volume and trabecular number, load to failure (Fmax), and yield load in long bones and vertebrae in ovariectomized rats, and increased trabecular separation in ovariectomized rats is fully prevented by all doses. [4] |
别名 | Boniva monohydrate, Bondronat monohydrate, Ibandronate sodium, 伊班膦酸钠单水合物, BM-210955, BM-21.0955, 伊班膦酸钠一水合物, RPR-102289A |
分子量 | 360.23 |
分子式 | C9H25NNaO8P2 |
CAS No. | 138926-19-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Insoluble
H2O: 10 mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 2.776 mL | 13.88 mL | 27.76 mL | 69.4001 mL |
5 mM | 0.5552 mL | 2.776 mL | 5.552 mL | 13.88 mL | |
10 mM | 0.2776 mL | 1.388 mL | 2.776 mL | 6.94 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ibandronate sodium monohydrate 138926-19-9 Apoptosis Others Ibandronate sodium Monohydrate Inhibitor Boniva monohydrate Boniva Bondronat Bondronat monohydrate Ibandronate sodium BM 210955 伊班膦酸钠单水合物 inhibit BM210955 BM-210955 Boniva Monohydrate BM-21.0955 伊班膦酸钠一水合物 RPR-102289A Bondronat Monohydrate inhibitor